Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis

NeuroSignals

Volumn 12, Issue 4-5, 2003, Pages 215-220

  Nguyen, Minh Dang ^a   Julien, Jean Pierre ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Cell cycle; Cyclin dependent kinase 5; Cytoskeleton; Neurodegeneration

Indexed keywords

CYCLIN DEPENDENT KINASE 5; CYTOSKELETON PROTEIN; M PROTEIN; PROTEIN P25; PROTEIN P29; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN; CELL CYCLE; DEREGULATION; HUMAN; MOTONEURON; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PROTEIN PHOSPHORYLATION; REVIEW; SPINAL CORD;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CELL CYCLE; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; HUMANS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0346119136     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074623     Document Type: Review

References (47)

1. Cleveland DW, Rothstein JD: From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806-819.
2. Julien JP: Amyotrophic lateral sclerosis: Unfolding the toxicity of the misfolded. Cell 2001;104:581-591.
3. Robertson J, Kriz J, Nguyen MD, Julien JP: Pathways to motor neuron degeneration in transgenic mouse models. Biochimie 2002;84:1151-1160.
4. Tannoch VJ, Hinds PW, Tsai LH: Cell cycle control. Adv Exp Med Biol 2000;465:127-140.
5. Morgan DO: Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997;13:261-291.
6. Dhavan R, Tsai LH: A decade of CDK5. Nat Rev Mol Cell Biol 2001;2:749-759.
7. Nguyen MD, Mushynski WE, Julien JP: Cyclin at the interface between neurodevelopment and neurodegeneration. Cell Death Differ 2002;9:1294-1306.
8. Bajaj NP, Al-Sarraj ST, Anderson V, Kibble M, Leigh N, Miller CC: Cyclin-dependent kinase-5 is associated with lipofuscin in motor neurones in amyotrophic lateral sclerosis. Neurosci Lett 1998;245:45-48.
9. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999;402:615-622.
10. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH: Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000;405:360-364.
11. Patzke H, Tsai LH: Calpain-mediated cleavage of the cyclin-dependent kinase 5 activator p39 to p29. J Biol Chem 2002;277:8054-8060.
12. Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S: Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 2000;275:17166-17172.
13. Nath R, Davis M, Probert AW, Kupina NC, Ren X, Schielke GP, Wang KK: Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem Biophys Res Commun 2000;274:16-21.
14. Tseng HC, Zhou Y, Shen Y, Tsai LH: A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett 2002;523:58-62.
15. Nguyen MD, Larivière RC, Julien JP: Deregulation of Cdk5 in a mouse model of ALS: Toxicity alleviated by perikaryal neurofilament inclusions. Neuron 2001;30:135-147.
16. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, Coskran T, Carlo A, Seymour PA, Burkhardt JE, Nelson RB, McNeish JD: Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A 2000;97:2910-2915.
17. Bian F, Nath R, Sobocinski G, Booher RN, Lipinski WJ, Callahan MJ, Pack A, Wang KK, Walker LC: Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J Comp Neurol 2002;446:257-266.
18. Humbert S, Dhavan R, Tsai L: p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J Cell Sci 2000;113:975-983.
19. Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH: p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5), is degraded by the ubiquitin-proteasome pathway. J Biol Chem 1998;273:24057-24064.
20. Saito T, Onuki R, Fujita Y, Kusakawa G, Ishiguro K, Bibb JA, Kishimoto T, Hisanaga S: Developmental regulation of the proteolysis of the p35 cyclin-dependent kinase 5 activator by phosphorylation. J Neurosci 2003;23:1189-1197.
21. Urushitani M, Kurisu J, Tsukita K, Takahashi R: Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J Neurochem 2002:83:1030-1042.
22. Patzke H, Tsai LH: Cdk5 sinks into ALS. Trends Neurosci 2002;25:8-10.
23. Wang J, Xu G, Gonzales V, Coonfield M, Fromholt D, Copeland NG, Jenkins NA, Borchelt DR: Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol Dis 2002;10:128-138.
24. Lefebvre S, Mushynski WE: Calcium binding to untreated and dephosphorylated porcine neurofilaments. Biochem Biophys Res Commun 1987;145:1006-1011.
25. Lefebvre S, Mushynski WE: Characterization of the cation-binding properties of porcine neurofilaments. Biochemistry 1988;27:8503-8508.
26. 3H-thymidine incorporation and neurogenesis. J Neurosci 1993;13:2930-2938.
27. Tsai LH, Takahashi T, Caviness VS Jr, Harlow E: Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 1993;119:1029-1040.
28. Carey RG, Li B, DiCicco-Bloom E: Pituitary adenylate cyclase activating polypeptide anti-mitogenic signaling in cerebral cortical progenitors is regulated by p57Kip2-dependent CDK2 activity. J Neurosci 2002;22:1583-1591.
29. Liu DX, Greene LA: Neuronal apoptosis at the G1/S cell cycle checkpoint. Cell Tissue Res 2001;305:217-228.
30. Husseman JW, Nochlin D, Vincent I: Mitotic activation: A convergent mechanism for a cohort of neurodegenerative diseases. Neurobiol Aging 2000;21:815-828.
31. Park DS, Obeidat A, Giovanni A, Greene LA: Cell cycle regulators in neuronal death evoked by excitotoxic stress: Implications for neurodegeneration and its treatment. Neurobiol Aging 2000;21:771-781.
32. Osuga H, Osuga S, Wang F, Fetni R, Hogan MJ, Slack RS, Hakim AM, Ikeda JE, Park DS: Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci U S A 2000;97:10254-10259.
33. Giovanni A, Keramaris E, Morris EJ, Hou ST, O'Hare M, Dyson N, Robertson GS, Slack RS, Park DS: E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3. J Biol Chem 2000;275:11553-11560.
34. Liu DX, Greene LA: Regulation of neuronal survival and death by E2F-dependent gene repression and derepression. Neuron 2001;32:425-438.
35. Ranganathan S, Scudiere S, Bowser R: Hyperphosphorylation of the retinoblastoma gene product and altered subcellular distribution of E2F-1 during Alzheimer's disease and amyotrophic lateral sclerosis. J Alzheimers Dis 2001;3:377-385.
36. Ranganathan S, Bowser R: Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am J Pathol 2003;162:823-835.
37. Nguyen MD, Boudreau M, Kriz J, Couillard-Despres S, Kaplan DR, Julien JP: Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J Neurosci 2003;23:2131-2140.
38. Takashima A, Murayama M, Yasutake K, Takahashi H, Yokoyama M, Ishiguro K: Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci Lett 2001;306:37-40.
39. Kriz J, Nguyen MD, Julien JP: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:268-278.
40. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu du C, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochromecrelease and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-78.
41. Lee KY, Helbing CC, Choi KS, Johnston RN, Wang JH: Neuronal Cdc2-like kinase (Nclk) binds and phosphorylates the retinoblastoma protein. J Biol Chem 1997;272:5622-5626.
42. Zukerberg LR, Patrick GN, Nikolic M, Humbert S, Wu CL, Lanier LM, Gertler FB, Vidal M, Van Etten RA, Tsai LH: Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 2000;26:633-646.
43. Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C, Peters G: CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 1994;9:71-79.
44. Gong X, Tang X, Wiedmann M, Wang X, Peng J, Zheng D, Blair LA, Marshall J, Mao Z: Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 2003;38:33-46.
45. Xiong W, Pestell R, Rosner MR: Role of cyclins in neuronal differentiation of immortalized hippocampal cells. Mol Cell Biol 1997;17:6585-6597.
46. Zheng M, Leung CL, Liem RK: Region-specific expression of cyclin-dependent kinase 5 (cdk5) and its activators, p35 and p39, in the developing and adult rat central nervous system. J Neurobiol 1998;35:141-159.
47. Cai XH, Tomizawa K, Tang D, Lu YF, Moriwaki A, Tokuda M, Nagahata S, Hatase O, Matsui H: Changes in the expression of novel Cdk5 activator messenger RNA (p39nck5ai mRNA) during rat brain development. Neurosci Res 1997;28:355-360.